Melanoma

Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Urinary BladderAn Open-Label, Phase 1 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AB821 in Adult Participants With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
Melanoma, SkinR3767-ONC-22122: A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatilimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma
Kidney, Melanoma, SkinA Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) in Patients With Advanced Solid Organ Malignancies
Kidney, Melanoma, SkinA Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma
Kidney, Lip, Oral Cavity and Pharynx, Lung, Melanoma, SkinXTX301 in Patients With Advanced Solid Tumors